Month: February 2021

ITI-1284 is a deuterated form of lumateperone delivered sublingually as an orally disintegrating tablet (ODT-SL). ITI-1284 ODT-SL may offer pharmacologic benefits and ease-of-use for patients, particularly in elderly populations.Phase 1 single ascending dose and multiple ascending dose studies have been completed in healthy volunteers including elderly subjects > than 65 years of age.Company plans to develop ITI-1284 for the treatment of behavioral disturbances in dementia, dementia-related psychosis, and certain depressive disorders in the elderly.NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the expansion of its pipeline with ITI-1284...

TORONTO, Feb. 24, 2021 (GLOBE NEWSWIRE) — Gowest Gold Ltd. (“Gowest” or the “Company”) (TSX VENTURE: GWA) is pleased to provide an update on the processing of the first gold ore from the Company’s 100% owned Bradshaw Gold Deposit (“Bradshaw”).In late January 2021, Gowest successfully completed processing 23,000 tonnes of the gold-bearing mixed development, unclassified material (see Gowest release dated Dec. 9, 2020) stockpiled during the commencement of its bulk sample program at Bradshaw. The Company had planned to first process this unclassified gold-bearing material in order to gather valuable evidence of how it responds to ore-sorting, grinding, flotation, dewatering and concentrate smelting. This trial has also demonstrated that the mill site water quality and tailings impoundment were in regulatory compliance confirming that...

Reports quarterly revenue of $108.6 million, representing 56% year-over-year growth, and annual revenue of $366.3 million represents 36% year-over-year growthOrganic revenue growth was 47% for the fourth quarter and 29% for the year 2020WALTHAM, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2020. Provided in this press release are financial highlights for the three – and twelve-month periods ended December 31, 2020, followed by our current financial guidance for the year 2021, and access information for today’s webcast and conference call.Tony J. Hunt, President and Chief Executive Officer said, “We are delighted with the way we finished off 2020 with 47%...

TORONTO, Feb. 24, 2021 (GLOBE NEWSWIRE) — Troilus Gold Corp. (TSX: TLG; OTCQB: CHXMF) (“Troilus” or the “Company”) reports additional drill results from recent exploration drilling at its 100%-owned Troilus Gold Project (“Troilus” or the “Project”) located in north central Quebec, Canada. These latest results represent exploration and step out holes located in the Southwest Zone, a priority growth target which was discovered and drilled in late 2019 and early 2020 (See Figure 1). Results continue to define significant mineral expansion well beyond the pit proposed in the Preliminary Economic Assessment (“PEA”) (See press release dated August 31, 2020) (See Figure 2). Highlights include:ZSW20-209 extended known mineralization an additional 250 metres east of the PEA defined pit shell, over 225m below it and remains open, suggesting...

WILMETTE, Ill., Feb. 24, 2021 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler D. Robinson, MD, Chief Executive Officer, is planning to present a Company overview at the following investor conferences in March:H.C. Wainwright Global Life Sciences ConferenceThe Company’s presentation will be webcast on Tuesday, March 9, 2021 at 7:00 a.m. ET33rd Annual Roth Conference, HealthcareThe Company’s fireside chat will be webcast on Tuesday, March 16, 2021 at 12:00 p.m. ETMaxim’s 2021 Emerging Growth Virtual ConferencePresentation time to be determined on Wednesday, March 17, 2021About Monopar Therapeutics Inc.Monopar Therapeutics...

– Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations –– KO-539 continues to demonstrate a wide therapeutic window in dose escalation; protocol amendment to include genetically enriched Phase 1 expansion cohorts –– Tipifarnib receives Breakthrough Therapy Designation from FDA –– $633.3 million in cash, cash equivalents and investments provide runway into 2024 –– Management to host webcast and conference call today at 8:00 a.m. ET –SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2020 financial results and provided a corporate...

NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) — Cowen Sustainable Investments (“CSI”), a private sustainability investment strategy within the investment management division of Cowen Inc. (NASDAQ:COWN), today announced it has successfully raised $919 million for its inaugural fund, bringing CSI platform assets to over $1.1 billion. CSI secured commitments from leading institutional investors, sovereign wealth funds and public pension funds, in addition to family offices, and foundations from around the world. The CSI platform leverages its partnership with investors to provide scaled, multi-hundred million dollar capital solutions per investment.CSI was established in 2018 to provide tailored financing and data analytics solutions to companies that are accelerating the world’s transition towards an environmentally sustainable economy....

Sjá meðfylgjandi viðhengi.ViðhengiSíminn hf. – Viðskipti fjárhagslega tengds aðila – Atburður ehf. 240221

An Emerging Markets Sponsored CommentaryORLANDO, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) — Transformative.That’s the key word in a very recent headline for today’s editorial feature regarding diversified health and wellness, beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) which reported that it has closed its previously announced acquisition of Naturo Group Investments Inc. (“Naturo”).You’ll forgive us for not bringing the news of the prospective deal to your digital door but we favor done deals to unfinished works in The EMR.It’s a fascinating acquisition for a cannabis company positioned in a marketplace with renewed affection for the sector and now adding Naturo’s innovative plant-based mineral beverage and supplement brand, TRACE, and significant manufacturing infrastructure and international...

ALPHARETTA, Ga., Feb. 24, 2021 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its fourth quarter and full year 2020 financial results will be reported on Wednesday, March 10, 2021 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (844) 263-8310 (domestic) or (213) 358-0959 (international) and entering conference code: 5286349. An archive of the webcast...